Non-canonical Functions of the RB Protein in Cancer

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2018 Apr 26

PMID 29692417

Citations 93

Authors

Frederick A Dick

David W Goodrich

Julien Sage

Nicholas J Dyson

Affiliations

Soon will be listed here.

Abstract

The canonical model of RB-mediated tumour suppression developed over the past 30 years is based on the regulation of E2F transcription factors to restrict cell cycle progression. Several additional functions have been proposed for RB, on the basis of which a non-canonical RB pathway can be described. Mechanistically, the non-canonical RB pathway promotes histone modification and regulates chromosome structure in a manner distinct from cell cycle regulation. These functions have implications for chemotherapy response and resistance to targeted anticancer agents. This Opinion offers a framework to guide future studies of RB in basic and clinical research.

Citing Articles

Increasing RB1 Expression by Targeting EZH2 in Triple-Negative Breast Cancer.

Yang R, Fei L, Xue Y, Zhang Y, Hu Q, Guo L J Cell Mol Med. 2025; 29(5):e70384.

PMID: 40070134 PMC: 11897054. DOI: 10.1111/jcmm.70384.

Chromothripsis-Mediated Small Cell Lung Carcinoma.

Rekhtman N, Tischfield S, Febres-Aldana C, Lee J, Chang J, Herzberg B Cancer Discov. 2024; 15(1):83-104.

PMID: 39185963 PMC: 11726019. DOI: 10.1158/2159-8290.CD-24-0286.

APC/C prevents a noncanonical order of cyclin/CDK activity to maintain CDK4/6 inhibitor-induced arrest.

Mouery B, Baker E, Mei L, Wolff S, Mills C, Fleifel D Proc Natl Acad Sci U S A. 2024; 121(30):e2319574121.

PMID: 39024113 PMC: 11287123. DOI: 10.1073/pnas.2319574121.

EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non-small cell lung cancer.

Yang C, Ma S, Zhang J, Han Y, Wan L, Zhou W Proc Natl Acad Sci U S A. 2024; 121(23):e2317790121.

PMID: 38814866 PMC: 11161775. DOI: 10.1073/pnas.2317790121.

Genetic markers associated with ferroptosis in Alzheimer's disease.

Sun Y, Xiao Y, Tang Q, Chen W, Lin L Front Aging Neurosci. 2024; 16:1364605.

PMID: 38711596 PMC: 11073811. DOI: 10.3389/fnagi.2024.1364605.

References

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

Bruce J, Hurford Jr R, Classon M, Koh J, Dyson N . Requirements for cell cycle arrest by p16INK4a. Mol Cell. 2000; 6(3):737-42. DOI: 10.1016/s1097-2765(00)00072-1. View

Varma H, Conrad S . Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain. Oncogene. 2000; 19(41):4746-53. DOI: 10.1038/sj.onc.1203827. View

Chan H, Krstic-Demonacos M, Smith L, Demonacos C, La Thangue N . Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell Biol. 2001; 3(7):667-74. DOI: 10.1038/35083062. View

Zheng L, Flesken-Nikitin A, Chen P, Lee W . Deficiency of Retinoblastoma gene in mouse embryonic stem cells leads to genetic instability. Cancer Res. 2002; 62(9):2498-502. View

Sherr C, McCormick F . The RB and p53 pathways in cancer. Cancer Cell. 2002; 2(2):103-12. DOI: 10.1016/s1535-6108(02)00102-2. View

Calbo J, Parreno M, Sotillo E, Yong T, Mazo A, Garriga J . G1 cyclin/cyclin-dependent kinase-coordinated phosphorylation of endogenous pocket proteins differentially regulates their interactions with E2F4 and E2F1 and gene expression. J Biol Chem. 2002; 277(52):50263-74. DOI: 10.1074/jbc.M209181200. View

Classon M, Harlow E . The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer. 2002; 2(12):910-7. DOI: 10.1038/nrc950. View

Wells J, Yan P, Cechvala M, Huang T, Farnham P . Identification of novel pRb binding sites using CpG microarrays suggests that E2F recruits pRb to specific genomic sites during S phase. Oncogene. 2003; 22(10):1445-60. DOI: 10.1038/sj.onc.1206264. View

10.

Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J . Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003; 4(3):209-21. DOI: 10.1016/s1535-6108(03)00215-0. View

11.

Dick F, Dyson N . pRB contains an E2F1-specific binding domain that allows E2F1-induced apoptosis to be regulated separately from other E2F activities. Mol Cell. 2003; 12(3):639-49. DOI: 10.1016/s1097-2765(03)00344-7. View

12.

Avni D, Yang H, Martelli F, Hofmann F, ElShamy W, Ganesan S . Active localization of the retinoblastoma protein in chromatin and its response to S phase DNA damage. Mol Cell. 2003; 12(3):735-46. DOI: 10.1016/s1097-2765(03)00355-1. View

13.

Mayhew C, Perkin L, Zhang X, Sage J, Jacks T, Knudsen E . Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents. Oncogene. 2004; 23(23):4107-20. DOI: 10.1038/sj.onc.1207503. View

14.

Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-39. DOI: 10.1056/NEJMoa040938. View

15.

Maddison L, Sutherland B, Barrios R, Greenberg N . Conditional deletion of Rb causes early stage prostate cancer. Cancer Res. 2004; 64(17):6018-25. DOI: 10.1158/0008-5472.CAN-03-2509. View

16.

Ludovini V, Gregorc V, Pistola L, Mihaylova Z, Floriani I, Darwish S . Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer. Lung Cancer. 2004; 46(1):77-85. DOI: 10.1016/j.lungcan.2004.03.018. View

17.

Kobayashi S, Boggon T, Dayaram T, Janne P, Kocher O, Meyerson M . EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352(8):786-92. DOI: 10.1056/NEJMoa044238. View

18.

Gonzalo S, Garcia-Cao M, Fraga M, Schotta G, Peters A, Cotter S . Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nat Cell Biol. 2005; 7(4):420-8. DOI: 10.1038/ncb1235. View

19.

Xiao H, Goodrich D . The retinoblastoma tumor suppressor protein is required for efficient processing and repair of trapped topoisomerase II-DNA-cleavable complexes. Oncogene. 2005; 24(55):8105-13. PMC: 2799250. DOI: 10.1038/sj.onc.1208958. View

20.

Rubin S, Gall A, Zheng N, Pavletich N . Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. Cell. 2005; 123(6):1093-106. DOI: 10.1016/j.cell.2005.09.044. View